External broker reports(aggregated public sources), Masterlink Securities Corp

Masterlink Securities

External broker reports(aggregated public sources)

Equity Bottom-Up

<p>Lotus’ profits will remain upbeat thanks to stable market share for its main product Suboxone and its anti-obesity drug business in South Korea. Meanwhile, the company is making inroads into the global anti-cancer drugs market. Although Lotus has cut the price for Suboxone in Jul21, and trim 2H21 GM guidance to less than 45% as a result, we still expect overall sales to remain upbeat given strong sales growth in the overseas markets in 2H21-1H22. The main U.S. generic drug Lenalidomide will be launched in Sep22, which could contribute over NT$2 to FY22 EPS. Therefore, we forecast the firm’s FY21 and FY22 EPS at NT$6.09 and NT$10.78, respectively, and reiterate BUY on Lotus with a target price of NT$152 (25x FY21 EPS).</p><div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

Lotus’ profits will remain upbeat thanks to stable market share for its main product Suboxone and its anti-obesity drug business in South Korea. Meanwhile, the company is making inroads into the global anti-cancer drugs market. Although Lotus has cut the price for Suboxone in Jul21, and trim 2H21 GM guidance to less than 45% as a result, we still expect overall sales to remain upbeat given strong sales growth in the overseas markets in 2H21-1H22. The main U.S. generic drug Lenalidomide will be launched in Sep22, which could contribute over NT$2 to FY22 EPS. Therefore, we forecast the firm’s FY21 and FY22 EPS at NT$6.09 and NT$10.78, respectively, and reiterate BUY on Lotus with a target price of NT$152 (25x FY21 EPS).Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Lotus Pharmaceutical (1795 TT) Growth Story for Blood Cancer Drugs

Taiwan

Lotus Pharmaceutical Co., Ltd. manufactures and distributes oral medicine, ointment and injection medicine.

Lotus Pharmaceutical (1795 TT) Growth Story for Blood Cancer Drugs

Lotus’ profits will remain upbeat thanks to stable market share for its main product Suboxone and its anti-obesity drug business in South Korea....

Masterlink Securities